论文部分内容阅读
目的:观察替罗非班对急性冠脉综合征(ACS)患者经皮冠状动脉成形术(PCI)术后基质金属蛋白酶-9(MMP-9)及白介素-6(IL-6)水平的影响。方法:选择我院2007年2月～2008年12月住院的ACS患者68例,随机分为对照组(n=34)和替罗非班组(n=34)。两组均急诊行PCI术,分别于PCI术前及术后12 h,用ELISA法检测患者血清MMP-9及IL-6的水平。结果:替罗非班组与对照组相比,PCI术前两组之间MMP-9及IL-6的差异无统计学意义;PCI术后12 h,二者MMP-9的水平[(492±65)vs.(560±82)μg/L]和IL-6的水平[(46.0±7.2)vs.(59.7±8.2)ng/L]差异明显(P<0.05)。结论:血小板GPⅡb/Ⅲa受体拮抗剂替罗非班能显著降低ACS患者介入术后MMP-9及IL-6的水平,抑制炎症反应,从而对血管具有一定的保护作用。
Objective: To observe the effects of tirofiban on the levels of matrix metalloproteinase-9 (MMP-9) and interleukin-6 (IL-6) after percutaneous transluminal coronary angioplasty (PCI) in patients with acute coronary syndrome . Methods: A total of 68 ACS patients admitted to our hospital from February 2007 to December 2008 were randomly divided into control group (n = 34) and tirofiban group (n = 34). The patients in both groups underwent emergency PCI, and the levels of serum MMP-9 and IL-6 were detected by ELISA before and 12 h after PCI respectively. Results: Compared with the control group, there was no significant difference in the levels of MMP-9 and IL-6 between the two groups before PCI; at 12 h after PCI, the levels of MMP-9 [(492 ± (P <0.05). The difference between the two groups was statistically significant (P <0.05). Conclusion: The platelet GPⅡb / Ⅲa receptor antagonist, tirofiban, can significantly decrease the levels of MMP-9 and IL-6 after interventional therapy in patients with ACS and inhibit the inflammatory reaction, thus having a certain protective effect on blood vessels.